Developing new hope for patients and families

APPROVED PRODUCTS

Currently, VIVUS has no products approved for use in the U.S. for the treatment of PAH.

INVESTIGATION & DEVELOPMENT

Pulmonary Arterial Hypertension (PAH) is a degenerative and life-threatening disease that makes it difficult for the heart to pump blood to the lungs to be oxygenated and may ultimately lead to heart failure. Current PAH treatment options only address the symptoms, slowing but not preventing disease progression. New therapies that address the underlying cause of disease are urgently needed.

In January 2017, VIVUS acquired exclusive, worldwide rights covering the ability to conduct preclinical work, clinical trials, and regulatory filings as well as the eventual marketing, sale, and distribution of PAH treatments using tacrolimus and ascomycin, should approvals be obtained.

Pulmonary arterial hypertension is a degenerative disease with current treatment options that only address the symptoms to slow the progression of the disease. We are excited about the potential of developing treatment options to significantly improve the quality of life and life expectancy of PAH patients.

LINKS AND INFORMATION